Tom Wilemon

Eng named to GI cancer leadership position at VICC

Cathy Eng, MD, a national and international leader in gastrointestinal medical oncology, is joining Vanderbilt-Ingram Cancer Center (VICC).

Treatment approved for patients with acute graft-versus-host disease

The U.S. Food and Drug Administration (FDA) recently approved ruxolitinib, the first drug for patients with acute graft-versus-host disease (GVHD) who have an inadequate response to steroid treatment. VUMC’s Madan Jagasia, MBBS, MS, MMHC, was a lead investigator of the REACH1 trial that was the basis for the FDA approval.

Immunotherapy helping 87-year-old man stay on the job

Nine years after being diagnosed with metastatic lung cancer, Roszell Mack Jr., 87, still goes into the office every day thanks to a durable response to the immunotherapy pembrolizumab.

Bioimpedance spectroscopy better than tape measure for identifying lymphedema risk

Bioimpedance spectroscopy (BIS) is better than a tape measure for assessing a woman’s risk for developing lymphedema.

Cancer Center’s annual scientific retreat set for May 1

The varying roles that signaling molecules play in progression of cancer is the focus of the Vanderbilt-Ingram Cancer Center 20th Annual Scientific Retreat when some of the nation’s top experts will speak about “Signal Transduction in Cancer Initiation, Progression and Treatment.”

Doctor and patient compete for honor

1 19 20 21 22 23 34